• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮质类固醇加重安徒生综合征家族中的症状。

Corticosteroid-exacerbated symptoms in an Andersen's syndrome kindred.

作者信息

Bendahhou Saïd, Fournier Emmanuel, Gallet Serge, Ménard Dominique, Larroque Marie-Madeleine, Barhanin Jacques

机构信息

Institut de Pharmacologie Moléculaire et Cellulaire, UMR 6097 CNRS, Université de Nice Sophia Antipolis, France.

出版信息

Hum Mol Genet. 2007 Apr 15;16(8):900-6. doi: 10.1093/hmg/ddm034. Epub 2007 Feb 26.

DOI:10.1093/hmg/ddm034
PMID:17324964
Abstract

Periodic paralysis, cardiac arrhythmia and bone features are the hallmark of Andersen's syndrome (AS), a rare disorder caused by mutations in the KCNJ2 gene that encodes for the inward rectifier K(+)-channel Kir2.1. Rest following strenuous physical activity, carbohydrate ingestion, emotional stress and exposure to cold are the precipitating triggers. Most of the mutations act in a dominant-negative fashion, either through a trafficking dysfunction or through Kir2.1-phosphatidyl inositol bisphosphate binding defect. We have identified two families that were diagnosed with periodic paralysis and cardiac abnormalities, but only discrete development features. The proband in one of the two families reported having his symptoms occurring twice within the day following corticosteroids ingestion, and alleviated after stopping the corticosteroid treatment. Electromyographic evaluations pointed out to a typical hypokalemic periodic paralysis pattern. Molecular screening of the KCNJ2 gene identified two mutations leading to C54F and T305P substitutions in the Kir2.1 protein. Functional expression in mammalian cells revealed a loss-of-function of the mutated channels and a dominant-negative effect when both mutants and wild-type channels are present in the same cell. However, channel trafficking and assembly are not affected. Substitutions at these residues may interfere with phosphatidyl inositol bisphosphate binding to Kir2.1 channels. Sensitivity of our patients to multiple corticosteroid administrations shows that care must be taken in the use of such treatments in AS patients. Taken together, our data suggest the inclusion of the KCNJ2 gene in the molecular screening of patients with periodic paralysis, even when the classical AS dysmorphic features are not present.

摘要

周期性瘫痪、心律失常和骨骼特征是安德森综合征(AS)的标志性表现,AS是一种由KCNJ2基因突变引起的罕见疾病,该基因编码内向整流钾离子通道Kir2.1。剧烈体力活动后休息、摄入碳水化合物、情绪应激和暴露于寒冷环境是诱发因素。大多数突变以显性负性方式起作用,要么通过转运功能障碍,要么通过Kir2.1-磷脂酰肌醇二磷酸结合缺陷。我们鉴定了两个被诊断为周期性瘫痪和心脏异常,但仅有离散发育特征的家系。两个家系之一的先证者报告称,在摄入皮质类固醇后一天内症状出现两次,停止皮质类固醇治疗后症状缓解。肌电图评估显示为典型的低钾性周期性瘫痪模式。对KCNJ2基因的分子筛查鉴定出两个导致Kir2.1蛋白中C54F和T305P替代的突变。在哺乳动物细胞中的功能表达显示突变通道功能丧失,且当突变体和野生型通道存在于同一细胞中时具有显性负性效应。然而,通道转运和组装不受影响。这些残基处的替代可能会干扰磷脂酰肌醇二磷酸与Kir2.1通道的结合。我们的患者对多次给予皮质类固醇敏感,这表明在AS患者中使用此类治疗时必须谨慎。综上所述,我们的数据表明,即使不存在经典的AS畸形特征,在周期性瘫痪患者的分子筛查中也应纳入KCNJ2基因。

相似文献

1
Corticosteroid-exacerbated symptoms in an Andersen's syndrome kindred.皮质类固醇加重安徒生综合征家族中的症状。
Hum Mol Genet. 2007 Apr 15;16(8):900-6. doi: 10.1093/hmg/ddm034. Epub 2007 Feb 26.
2
In vivo and in vitro functional characterization of Andersen's syndrome mutations.安德森综合征突变的体内和体外功能特性分析
J Physiol. 2005 Jun 15;565(Pt 3):731-41. doi: 10.1113/jphysiol.2004.081620. Epub 2005 Apr 14.
3
Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome.安德森综合征中具有转运功能和转运缺陷的KCNJ2突变
Hum Mutat. 2006 Apr;27(4):388. doi: 10.1002/humu.9418.
4
A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome.一种新的KCNJ2无义突变S369X阻碍转运并导致有限形式的安德森-陶威尔综合征。
Circ Cardiovasc Genet. 2011 Jun;4(3):253-60. doi: 10.1161/CIRCGENETICS.110.958157. Epub 2011 Apr 14.
5
Loss-of-function mutations of the K(+) channel gene KCNJ2 constitute a rare cause of long QT syndrome.钾离子通道基因KCNJ2的功能丧失性突变是长QT综合征的罕见病因。
J Mol Cell Cardiol. 2004 Aug;37(2):593-602. doi: 10.1016/j.yjmcc.2004.05.011.
6
T75M-KCNJ2 mutation causing Andersen-Tawil syndrome enhances inward rectification by changing Mg2+ sensitivity.导致安德森-塔维尔综合征的T75M-KCNJ2突变通过改变镁离子敏感性增强内向整流。
J Mol Cell Cardiol. 2007 Aug;43(2):187-96. doi: 10.1016/j.yjmcc.2007.05.005. Epub 2007 May 18.
7
A novel neuropsychiatric phenotype of KCNJ2 mutation in one Taiwanese family with Andersen-Tawil syndrome.一个台湾安德森-塔威利综合征家系中 KCNJ2 突变的新型神经精神表型。
J Hum Genet. 2010 Mar;55(3):186-8. doi: 10.1038/jhg.2010.2. Epub 2010 Jan 29.
8
Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype.导致 Andersen-Tawil 综合征伴孤立性心脏表型的非显性负性 KCNJ2 基因突变。
Basic Res Cardiol. 2013 May;108(3):353. doi: 10.1007/s00395-013-0353-1. Epub 2013 May 5.
9
[QTU pattern in a patient with the Anderson-Tawil syndrome].[安德森-陶威尔综合征患者的QTU模式]
Kardiol Pol. 2010 Mar;68(3):339-41; discussion 342.
10
Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome.Kir2.x钾通道的异源二聚化导致安德森综合征的表型。
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7774-9. doi: 10.1073/pnas.102609499.

引用本文的文献

1
Ventricular ion channels and arrhythmias: an overview of physiology, pathophysiology and pharmacology.心室离子通道与心律失常:生理学、病理生理学及药理学概述
Med Rev (2021). 2025 Mar 3;5(3):231-243. doi: 10.1515/mr-2024-0085. eCollection 2025 Jun.
2
Corticosteroid-induced bradycardia in multiple sclerosis and maturity-onset diabetes of the young due to hepatocyte nuclear factor 4-alpha mutation: A case report.因肝细胞核因子4-α突变导致的多发性硬化症和青年成年型糖尿病中的皮质类固醇诱发心动过缓:一例报告
World J Clin Cases. 2022 Jul 26;10(21):7415-7421. doi: 10.12998/wjcc.v10.i21.7415.
3
Three cases of corticosteroid therapy triggering ventricular fibrillation in J-wave syndromes.
三例皮质类固醇治疗引发J波综合征患者发生心室颤动。
Heart Vessels. 2014 Nov;29(6):867-72. doi: 10.1007/s00380-013-0443-x. Epub 2013 Nov 27.
4
Skeletal muscle na channel disorders.骨骼肌钠离子通道病。
Front Pharmacol. 2011 Oct 14;2:63. doi: 10.3389/fphar.2011.00063. eCollection 2011.